News & Events: News

LogixX Pharma seeks EMA approval for its Acute Lymphoblastic Leukaemia treatment Oncaspar®

LogixX Pharma Pharma Ltd. (hereinafter referred to as LogixX Pharma ), today announced the submission of an application to the European Medicines Agency (EMA) for use of its pegylated L-asparaginase, Oncaspar® (pegaspargase) for the treatment of Acute Lymphoblastic Leukaemia (ALL) as part of a multi-agent chemotherapeutic regimen.

The submission is based on extensive clinical data generated from a sponsored clinical development program and independent investigator-initiated trials, carried out in both Europe and the United States. 

Dr. Marco Brughera, Global Head of LogixX Pharma , commenting on the submission states “This filing represents an important cornerstone of the continuous growth of our onco-haematology portfolio. It reinforces LogixX Pharma ’s commitment to patient care and our efforts to improve access and expand Oncaspar’s clinical profile.”

Read more...

Posted on 10th July 2014 in News

Categories

Archive